The efficacy of clarithromycin and the bicyclolide EDP-420 against Mycobacterium avium in a mouse model of pulmonary infection

Journal of Infectious Diseases

Volumn 197, Issue 11, 2008, Pages 1506-1510

  Bermudez, Luiz E ^a,b   Motamedi, Nima ^a   Kolonoski, Peter ^a   Chee, Chris ^a   Baimukanova, Gail ^a   Bildfell, Robert ^b   Wang, Guoqiang ^c   Ly, Tam Phan ^c   Young, Lowell S ^a  

^a Kuzell Institute for Arthritis and Infectious Diseases   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c Enanta Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 ACETYLIMINO 3 DEHEXAPYRANOSYLOXY 9 DEOXO 3 OXO 6 O,11 O [2 [6 (1 PYRAZOLYL) 3 PYRIDINYLMETHOXYIMINO]PROPYLENE]ERYTHROMYCIN; CLARITHROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; LUNG INFECTION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; ANTITUBERCULAR AGENTS; BRIDGED COMPOUNDS; CLARITHROMYCIN; FEMALE; LUNG; MACROLIDES; MICE; MICE, INBRED C57BL; MYCOBACTERIUM AVIUM; TUBERCULOSIS, PULMONARY;

EID: 43949115170     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/587906     Document Type: Article

References (31)

1. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367-416.
2. Rosenzweig DY. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases. Chest 1979; 75:115-9.
3. Falkinham JO III. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 1996; 9:177-215.
4. Inderlied CB, Kemper CA, Bermudez LE. The Mycobacterium avium complex. Clin Microbiol Rev 1993; 6:266-310.
5. Falkinham JO III, Norton CD, LeChevallier MW. Factors influencing numbers of Mycobacterium avium, Mycobacterium intracellulare, and other Mycobacteria in drinking water distribution systems. Appl Environ Microbiol 2001; 67:1225-31.
6. Horsburgh CRJ. Epidemiology of Mycobacterium avium complex. In: Korvick JA, ed. Mycobacterium avium-complex infection. Vol. 87. New York: Marcel Dekker, 1996:1-22.
7. Fujita J, Ohtsuki Y, Suemitsu I, et al. Pathological and radiological changes in resected lung specimens in Mycobacterium avium intracellulare complex disease. Eur Respir J 1999; 13:535-40.
8. Kubo K, Yamazaki Y, Masubuchi T, et al. Pulmonary infection with Mycobacterium avium-intracellulare leads to air trapping distal to the small airways. Am J Respir Crit Care Med 1998; 158:979-84.
9. Aksamit TR. Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin Chest Med 2002; 23:643-53.
10. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321:863-8.
11. Ebert DL, Olivier KN. Nontuberculous mycobacteria in the setting of cystic fibrosis. Clin Chest Med 2002; 23:655-63.
12. Huang JH, Kao PN, Adi V, Ruoss SJ. Mycobacterium avium- intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest 1999; 115:1033-40.
13. Wallace RJ Jr, Zhang Y, Brown BA, et al. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med 1998; 158:1235-44.
14. Yamazaki Y, Danelishvili L, Wu M, et al. The ability to form biofilm influences Mycobacterium avium invasion and translocation of bronchial epithelial cells. Cell Microbiol 2006; 8:806-14.
15. Walters MC III, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003; 47:317-23.
16. Wallace RJ, Zhang Y, Brown-Elliott BA, et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis 2002; 186:266-73.
17. Primack SL, Logan PM, Hartman TE, Lee KS, Muller NL. Pulmonary tuberculosis and Mycobacterium avium-intracellulare: a comparison of CT findings. Radiology 1995; 194:413-7.
18. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern: the Lady Windermere syndrome. Chest 1992; 101:1605-9.
19. Scorneaux B, Arya A, Polemeropoulos A, et al. In vitro and in vivo evaluation of EP-13420: a novel ketolide highly active against resistant pathogens and having exceptional pharmacokinetic properties in the dog [abstract F-1191]. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2003.
20. Qiu Y, Long J, Luo X, et al. In vitro and in vivo evaluation of EP-014598: a new bicyclolide active against resistant pathogens with exceptional pharmacokinetic profiles [abstract F1-1677]. In: Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007: 247.
21. Bermudez L, Inderlied CB, Kolonoski P, Wu M, Young LS. Activity of HMR3004 against Mycobacterium avium complex in vitro, in human macrophages and in beige mice. Clin Microbiol Infect 1998; 4:325-31.
22. Bermudez LE, Petrofsky M, Kolonoski P, Young LS. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. Antimicrob Agents Chemother 1998; 42:180-3.
23. Bermudez LE, Motamedi N, Chee C, et al. EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. Antimicrob Agents Chemother 2007; 51:1666-70.
24. Carter G, Young LS, Bermudez LE. A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. Antimicrob Agents Chemother 2004; 48:4907-10.
25. Yamazaki Y, Danelishvili L, Wu M, Macnab M, Bermudez LE. Mycobacterium avium genes associated with the ability to form a biofilm. Appl Environ Microbiol 2006; 72:819-25.
26. Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 174:928-34.
27. Lam PK, Griffith DE, Aksamit TR, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 173:1283-9.
28. Cooper AM, Appelberg R, Orme IM. Immunopathogenesis of Mycobacterium avium infection. Front Biosci 1998; 3:e141-8.
29. Furuie H, Irie S, Saisho Y, Yoshikawa T, Shimada J. Intrapulmonary pharmacokinetics (PK) of S-013420, a bicyclolide, in healthy Japanese subjects [abstract A-798]. In: Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007:23.
30. Jiang LJ, Wang M, Or YS. Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers [abstract A-800]. In: Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007:23.
31. Haagensen JA, Klausen M, Ernst RK, et al. Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol 2007; 189:28-37.